Clinical utility of gadobenate dimeglumine in contrast-enhanced MRI of the breast: a review

References

• Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.
   PubMed Web of Science ®Google Scholar
• Bary F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229–239.
   Web of Science ®Google Scholar
• Akinyemiju TF, Genkinger JM, Farhat M, et al. Residential environment and breast cancer incidence and mortality: a systematic review and meta-analysis. BMC Cancer. 2015;15:191.
   Web of Science ®Google Scholar
• Van den Broek AJ, Schmidt MK, van’t Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis. PLoS One. 2015;10(3):e0120189.
   PubMed Web of Science ®Google Scholar
• Warner E, Messermith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148(9):671–679.
   Web of Science ®Google Scholar
• Brem RF, Leniham MJ, Lieberman J, Torrente J. Screening breast ultrasound: past, present and future. AJR Am J Roentgenol. 2015;204(2):234–240.
   Web of Science ®Google Scholar
• Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469–8476.
   Web of Science ®Google Scholar
• Millet I, Pages E, Hoa D. Pearls and pitfalls in breast MRI. Br J Radiol. 2012;85(1011):197–207.
   Web of Science ®Google Scholar
• Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830–849.
   PubMed Web of Science ®Google Scholar
• Peters NH, Borel Rinkes IH, Zuitoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology. 2008;246(1):116–124.
   PubMed Web of Science ®Google Scholar
• Le-Petross HT, Shetty MK. Magnetic resonance imaging and breast ultrasonography as an adjunct to mammographic screening in high-risk patients. Semin Ultrasound CT MR. 2011;32(4):266–272.
   Web of Science ®Google Scholar
• Tharmaratnam K, Hagen AI, Moller P. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat. 2014;148(3):687–688.
   Web of Science ®Google Scholar
• Oztekin PS, Kosar PN. Magnetic Resonance Imaging of the breast as a problem solving method: to be or not to be? Breast J. 2014;20(6):622–631.
   Web of Science ®Google Scholar
• Sung JS, Li J, Da Costa G, et al. Preoperative breast MRI for early stage breast cancer: effect on surgical and long term outcomes. AJR Am J Roentgenol. 2014;2012(6):1376–1382.
   Google Scholar
• Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013;257(2):249–255.
   Web of Science ®Google Scholar
• Gonzalez V, Sandelin K, Karlsson A, et al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World J Surg. 2014;38(7):1685–1693.
   Web of Science ®Google Scholar
• Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol. 2011;46(2):94–105.
   PubMed Web of Science ®Google Scholar
• Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol. Epub 2015 May 23.
   Google Scholar
• Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008;66(2):160–167.
   PubMed Web of Science ®Google Scholar
• Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60(3):314–323.
   PubMed Web of Science ®Google Scholar
• Shen Y, Goerner FL, Snyder C, et al. T1 Relaxivities of Gadolinium Based Magnetic Resonance contrast agents in human whole blood at 1.5, 3 and 7 T. Invest Radiol. 2015;50(5):330–338.
   Web of Science ®Google Scholar
• Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol. 2003;181(3):663–676.
   Web of Science ®Google Scholar
• Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology. 2005;237(1):45–56.
   Web of Science ®Google Scholar
• Pediconi F, Catalano C, Padula S, et al. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. AJR Am J Roentgenol. 2008;191(5):1339–1346.
   Web of Science ®Google Scholar
• Martincich L, Faivre-Pierret M, Zechmann MC, et al. Multicenter, double-blind, randominzed, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT Trial). Radiology. 2011;258(2):396–408.
   Web of Science ®Google Scholar
• Gilbert FJ, van den Bosch HC, Petrillo A, et al. Comparison of gadobenate dimeglumine-enhanced breast MRI and gadopentetate dimeglumine-enhanced breast MRI with mammography and ultrasound for the detection of breast cancer. J Magn Reson Imaging. 2014;39(5):1272–1286.
   Web of Science ®Google Scholar
• Heywang SH, Hahn D, Schimdt H, et al. MR imaging of the breast using gadolinium DTPA. J Comput Assist Tomogr. 1986;10(2):199–204.
   Web of Science ®Google Scholar
• Renz DM, Durmus T, Bottcher J, et al. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast enhanced magnetic resonance imaging. Invest Radiol. 2014;49(7):474–484.
   Web of Science ®Google Scholar
• Fallenberg EM, Renz DM, Karle B, et al. Intraindividual randomized comparison of the macrocyclic contrast agent gadobutrol and gadoterate meglumine in breast magnetic resonance. Eur Radiol. 2015;25(3):837–849.
   Web of Science ®Google Scholar
• Carbonaro LA, Pediconi F, Verardi N, et al. Breast MRI using a high relaxivity contrast agent: an overview. AJR Am J Roentgenol. 2011 196(4):942–955.
   Google Scholar
• Pediconi F, Catalano C, Roselli A, et al. Contrast enhanced MR mammography for the evaluation of contralateral breasts in patients with diagnosed unilateral breast cancer or high-risks lesions. Radiology. 2007;243(3):670–680.
   Web of Science ®Google Scholar
• Viehweg P, Rotter K, Laniado M, et al. MR imaging of the contralateral breast in patients after breast-conserving therapy. Eur Radiol. 2004;14(3):402–408.
   Google Scholar
• Pediconi F, Kubik-Huch R, Chilla B, Schwenke C, Kinkel K. Intra-individual randomized comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M, in patients scheduled for preoperative breast MRI. Eur Radiol. 2013;23(1):84–92.
   Web of Science ®Google Scholar
• Schneider G, Fries P. Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol. 2013;23(8):2095–2096.
   Web of Science ®Google Scholar
• Sardanelli F, Fausto A, Esseridou A, Di Leo G, Kirchin MA. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol. 2008;43(4):236–242.
   Web of Science ®Google Scholar
• Carbonaro LA, Verardi N, Di Leo G, Sardanelli F. Handling a high relaxivity contrast material for dynamic breast MR imaging using higher thresholds for the initial enhancement. Invest Radiol. 2010;45(3):114–120.
   Web of Science ®Google Scholar
• Mahfouz AE, Sherif H, Saad A, et al. Gadolinium-enhanced MR angiography of the breast: is breast cancer associated with ipsilateral higher vascularity? Eur Radiol. 2001;11(6):965–969.
   Web of Science ®Google Scholar
• Carriero A, Di Credico A, Mansour M, Bonomo L. Maximun intensity projection analysis in magnetic resonance of the breast. J Exp Clin Cancer Res. 2002;21(3 Suppl):77–81.
   Web of Science ®Google Scholar
• Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral higher vascularity. Radiology. 2005;235(3):791–797.
   Web of Science ®Google Scholar
• Van der Molen AJ. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol. 2008;52(4):339–350.
   Web of Science ®Google Scholar
• Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo. July 2014;186(7):661–669.
   Google Scholar
• Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. Am J Roentgenol. 2015;205(3):469–478.
   Web of Science ®Google Scholar
• Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology. 2015;276(3):741–747.
   Web of Science ®Google Scholar